The effect of albendazole treatment on non-seizure outcomes in patients with symptomatic neurocysticercosis

Summary:

This study investigated the effect of albendazole on non-seizure symptoms experienced by patients with Neurocysticercosis (NC). Data was collected from a randomized controlled trial comparing albendazole plus prednisone with placebo plus prednisone for treatment of NC among 173 patients with active or transitional NC cysts and new-onset symptoms. Results showed 85% of patients reported at least one non-seizure symptom at baseline. Those treated with albendazole had significantly lower odds of memory loss and/or confusion during months 1–24 (odds ratio [OR] 0.42, p=0.037) and significantly increased odds of anxiety and/or depression during months 1–12 (OR 1.87, p=0.049). No treatment difference existed in experiencing symptoms in general or in experiencing headaches, limb weakness or gait disturbances, vomiting, nausea and/or stomach pain or visual disturbances over the follow-up period. It was concluded that while the prevalence of non-seizure symptoms was high, albendazole treatment was associated with only two significant differences in the non-seizure symptoms over follow-up. Further research is needed to identify strategies to reduce the long-term symptom burden in patients with NC.

Citation: Thapa K, Romo ML, Carpio A, Leslie D, Andrews H, Hauser WA, Kelvin EA. The effect of albendazole treatment on non-seizure outcomes in patients with symptomatic neurocysticercosis.  Transactions of The Royal Society of Tropical Medicine and Hygiene. 2018; 112 (2):73–80. https://doi.org/10.1093/trstmh/try023. Link to Article>>